Literature DB >> 10510796

Determination of ginsenoside Rg3 in plasma by solid-phase extraction and high-performance liquid chromatography for pharmacokinetic study.

H Wang1, H Zou, L Kong, Y Zhang, H Pang, C Su, G Liu, M Hui, L Fu.   

Abstract

A method using high-performance liquid chromatography (HPLC) and solid-phase extraction (SPE) is described for the determination of ginsenoside Rg3 in human plasma. A 2.5-ml volume of plasma was mixed with 2.5 ml 60% methanol aqueous solution, and centrifuged at 1100 g for 10 min, the supernatant fluid was further purified by SPE with 200 mg/5 ml 40 microns octadecyl silica and separation was obtained using a reversed-phase column under isocratic conditions with ultraviolet absorbance detection. The intra- and inter-day precision, determined as relative standard deviations, were less than 5.0%, and method recovery was more than 97%. The lower limit of quantitation, based on standards with acceptable RSDs, was 2.5 ng/ml. No endogenous compounds were found to interfere with analyte. A good linear relationship with a regression coefficient of 0.9999 in the range of 2.5 to 200 ng/ml was observed. This method has been demonstrated to be suitable for pharmacokinetic studies in humans. Method development for determination of drug with low UV absorption by SPE and HPLC is also discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510796     DOI: 10.1016/s0378-4347(99)00238-8

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  6 in total

1.  Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharacokinetic study in dogs.

Authors:  Hai-Tang Xie; Guang-Ji Wang; Hua Lv; Rui Wang Jian-Guo Sun; Xi-Ling Jiang; Hao Li; Wei Wang; Chen-Rong Huang; Mei-Juan Xu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

2.  Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors.

Authors:  Miao Hao; Wei Wang; Yuqing Zhao; Ruiwen Zhang; Hui Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-12-28       Impact factor: 2.441

3.  Ginsenosides Rb1 and Re decrease cardiac contraction in adult rat ventricular myocytes: role of nitric oxide.

Authors:  G I Scott; P B Colligan; B H Ren; J Ren
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

4.  Ginsenoside Re suppresses electromechanical alternans in cat and human cardiomyocytes.

Authors:  Y G Wang; A V Zima; X Ji; R Pabbidi; L A Blatter; S L Lipsius
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

5.  Pharmacokinetic Comparison of 20(R)- and 20(S)-Ginsenoside Rh1 and 20(R)- and 20(S)-Ginsenoside Rg3 in Rat Plasma following Oral Administration of Radix Ginseng Rubra and Sheng-Mai-San Extracts.

Authors:  Xiaomei Fan; Yan Xu; Danni Zhu; Yibing Ji
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-23       Impact factor: 2.629

6.  Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes.

Authors:  Miao Hao; Yuqing Zhao; Peizhan Chen; He Huang; Hong Liu; Hualiang Jiang; Ruiwen Zhang; Hui Wang
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.